Jazz Pharmaceuticals PLC has a consensus price target of $184.7, established from looking at the 67 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Cantor Fitzgerald, and Truist Securities on March 22, 2024, March 22, 2024, and March 20, 2024. With an average price target of $190 between JP Morgan, Cantor Fitzgerald, and Truist Securities, there's an implied 57.78% upside for Jazz Pharmaceuticals PLC from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/22/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 57.78% | JP Morgan | Jessica Fye | $170 → $190 | Maintains | Overweight | Get Alert |
03/22/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 49.48% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
03/20/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 66.09% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
03/20/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 56.12% | Piper Sandler | David Amsellem | $171 → $188 | Reiterates | Overweight → Overweight | Get Alert |
03/20/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 82.69% | Needham | Ami Fadia | → $220 | Reiterates | Buy → Buy | Get Alert |
03/15/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 91% | Stifel | Annabel Samimy | $225 → $230 | Maintains | Buy | Get Alert |
03/14/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 66.09% | HC Wainwright & Co. | Oren Livnat | $204 → $200 | Maintains | Buy | Get Alert |
03/01/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 91% | Barclays | Balaji Prasad | $235 → $230 | Maintains | Overweight | Get Alert |
03/01/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 8.79% | UBS | Ashwani Verma | $135 → $131 | Maintains | Neutral | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 49.48% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 61.93% | RBC Capital | Gregory Renza | → $195 | Reiterates | Outperform → Outperform | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 41.17% | JP Morgan | Jessica Fye | $180 → $170 | Maintains | Overweight | Get Alert |
02/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 82.69% | Needham | Ami Fadia | $225 → $220 | Maintains | Buy | Get Alert |
01/29/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 95.15% | Barclays | Balaji Prasad | $240 → $235 | Maintains | Overweight | Get Alert |
01/03/2024 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 32.87% | Baird | Joel Beatty | → $160 | Initiates | → Outperform | Get Alert |
12/04/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 66.09% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
11/29/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 86.85% | Needham | Ami Fadia | → $225 | Reiterates | Buy → Buy | Get Alert |
11/27/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 12.11% | UBS | Ashwani Verma | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
11/09/2023 | JAZZ | Buy Now | Jazz Pharmaceuticals | $120.42 | 58.61% | RBC Capital | Gregory Renza | $200 → $191 | Maintains | Outperform | Get Alert |
The latest price target for Jazz Pharmaceuticals (NASDAQ: JAZZ) was reported by JP Morgan on March 22, 2024. The analyst firm set a price target for $190.00 expecting JAZZ to rise to within 12 months (a possible 57.78% upside). 35 analyst firms have reported ratings in the last year.
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ: JAZZ) was provided by JP Morgan, and Jazz Pharmaceuticals maintained their overweight rating.
The last upgrade for Jazz Pharmaceuticals PLC happened on December 9, 2022 when Goldman Sachs raised their price target to $190. Goldman Sachs previously had a neutral for Jazz Pharmaceuticals PLC.
The last downgrade for Jazz Pharmaceuticals PLC happened on November 27, 2023 when UBS changed their price target from $170 to $135 for Jazz Pharmaceuticals PLC.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on March 22, 2024 so you should expect the next rating to be made available sometime around March 22, 2025.
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $170.00 to $190.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $120.42, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.